» Articles » PMID: 29127522

Common Genetic Variation Within MiR-146a Predicts Disease Onset and Relapse in Multiple Sclerosis

Overview
Journal Neurol Sci
Specialty Neurology
Date 2017 Nov 12
PMID 29127522
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Despite extensive studies focusing on the changes in expression of microRNAs (miRNAs) in multiple sclerosis (MS) compared to healthy controls, few studies have evaluated the association of genetic variants of miRNAs with MS clinical course. We investigated whether a functional polymorphism in the MS associated miR-146a gene predicted clinical course (hazard of conversion to MS and of relapse, and annualized change in disability), using a longitudinal cohort study of persons with a first demyelinating event followed up to their 5-year review. We found the genotype (GC+CC) of rs2910164 predicted relapse compared with the GG genotype (HR=2.09 (95% CI 1.42, 3.06), p=0.0001), as well as a near-significant (p=0.07) association with MS conversion risk. Moreover, we found a significant additive interaction between rs2910164 and baseline anti-EBNA-1 IgG titers predicting risk of conversion to MS (relative excess risk due to interaction [RERI] 2.39, p=0.00002) and of relapse (RERI 1.20, p=0.006). Supporting these results, similar results were seen for the other EBV-correlated variables: anti-EBNA-2 IgG titers and past history of infectious mononucleosis. There was no association of rs2910164 genotype for disability progression. Our findings provide evidence for miR-146a and EBV infection in modulating MS clinical course.

Citing Articles

Association of MicroRNA Expression and Serum Neurofilament Light Chain Levels with Clinical and Radiological Findings in Multiple Sclerosis.

Dominguez-Mozo M, Casanova I, Monreal E, Costa-Frossard L, Sainz-de-la-Maza S, Sainz-Amo R Int J Mol Sci. 2024; 25(18).

PMID: 39337499 PMC: 11432459. DOI: 10.3390/ijms251810012.


Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases.

Ashraf H, Solla P, Sechi L Pharmaceuticals (Basel). 2022; 15(9).

PMID: 36145298 PMC: 9504155. DOI: 10.3390/ph15091077.


Epstein-Barr Virus and Neurological Diseases.

Zhang N, Zuo Y, Jiang L, Peng Y, Huang X, Zuo L Front Mol Biosci. 2022; 8:816098.

PMID: 35083281 PMC: 8784775. DOI: 10.3389/fmolb.2021.816098.


MicroRNAs in Prion Diseases-From Molecular Mechanisms to Insights in Translational Medicine.

Contiliani D, Ribeiro Y, de Moraes V, Pereira T Cells. 2021; 10(7).

PMID: 34209482 PMC: 8307047. DOI: 10.3390/cells10071620.


miRNAs in Microglia: Important Players in Multiple Sclerosis Pathology.

Walsh A, Nguyen L, Binder M ASN Neuro. 2021; 13:1759091420981182.

PMID: 33517686 PMC: 7863159. DOI: 10.1177/1759091420981182.


References
1.
Hedstrom A, Lima Bomfim I, Barcellos L, Briggs F, Schaefer C, Kockum I . Interaction between passive smoking and two HLA genes with regard to multiple sclerosis risk. Int J Epidemiol. 2014; 43(6):1791-8. PMC: 4276064. DOI: 10.1093/ije/dyu195. View

2.
Waschbisch A, Atiya M, Linker R, Potapov S, Schwab S, Derfuss T . Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis. PLoS One. 2011; 6(9):e24604. PMC: 3174971. DOI: 10.1371/journal.pone.0024604. View

3.
Li Y, Du C, Wang W, Ma G, Cui L, Zhou H . Genetic association of MiR-146a with multiple sclerosis susceptibility in the Chinese population. Cell Physiol Biochem. 2015; 35(1):281-91. DOI: 10.1159/000369695. View

4.
Park R, Lee W, Ji J . Association between the three functional miR-146a single-nucleotide polymorphisms, rs2910164, rs57095329, and rs2431697, and autoimmune disease susceptibility: A meta-analysis. Autoimmunity. 2016; 49(7):451-458. DOI: 10.3109/08916934.2016.1171854. View

5.
Ascherio A, Munger K . Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol. 2007; 61(6):504-13. DOI: 10.1002/ana.21141. View